Interventional Therapy Department

The Department of Interventional Therapy of Peking University Cancer Hospital was established in 1996. It is one of the earliest comprehensive oncology interventional treatment centers established in China, with outpatient services, inpatient wards, an integrated interventional operating room, and integrated medical care, teaching, and research. It is a standardized training base for specialists of Peking University, a Capacity Building and Continuing Education Center of the National Health Commission, one of the first interventional medicine advanced-training bases, a standardized training base for interventional oncology treatment, a postdoctoral research station, and a core unit of the first group of National Radiology and Therapy Medical Research Centers, as well as a member institution of the Liver Cancer MDT Alliance of the Interventional Physicians Branch of the Chinese Medical Doctor Association. It is the institution of the chair of the Professional Committee of Oncology Interventional Treatment of the Chinese Anti-Cancer Association, the institution of the chair of the Professional Committee of Integrated Nursing in Oncology Interventional Treatment of the Chinese Anti-Cancer Association, and the institution of the president of the Interventional Specialists Branch of the Beijing Medical Doctor Association. The Department of Interventional Therapy has an integrated hybrid interventional operating room equipped with China's first large-bore Siemens Miyabi Angio-CT and a GE large-panel angiography system, Innova IGS540. It has large-field-of-view DSA, three-dimensional angiography, CBCT imaging, and tomographic reconstruction capabilities. In combination with imaging equipment such as ultrasound, it can perform microwave and cryoablation of various solid tumors; percutaneous particle implantation; venous infusion port implantation; percutaneous vertebroplasty (bone cement) for spinal metastases; image-guided puncture and catheterization of the radial artery, distal radial artery, and femoral artery for continuous arterial infusion chemotherapy; and hepatic artery catheterization (implantable pump) for targeted regional infusion chemotherapy and chemoembolization, Y90 radioembolization for malignant liver tumors, and other procedures. The department currently has 34 beds and 18 physicians, with more than 10,000 outpatient visits and 4,000 interventional procedures annually. Over the past five years, it has undertaken more than 10 national- and provincial-level research projects and conducted more than 20 clinical trial projects. In 2019, the clinical application project of continuous hepatic arterial infusion chemotherapy for malignant liver tumors won the Second Prize for Scientific and Technological Progress from the Chinese Anti-Cancer Association.